Inari Medical to Host First Analyst & Investor Day

Rhea-AI Summary

Inari Medical, Inc. (NASDAQ: NARI) announced its first Analyst and Investor Day scheduled for September 15, 2022, at its headquarters in Irvine, California. The event will involve a comprehensive update on the company’s business progress and future plans via a webcast set to begin at 9 a.m. Pacific Time. Participation is open to interested stakeholders, who can pre-register through a provided link. Additionally, a replay of the presentation will be available for 90 days on the company's Investor Relations website.

IRVINE, Calif., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that its management team will host the Company’s first Analyst and Investor Day on Thursday, September 15, 2022 at its headquarters in Irvine, CA.

The Company will provide an update on the Inari’s business progress and plans via a webcast, which will commence at approximately 9 a.m. Pacific Time.

If you would like to participate in this event, please click here to pre-register.

A live webcast replay of the presentation may be accessed for 90 days on the “Investor Relations” section of the company’s website at: https://www.inarimedical.com/.

About Inari Medical, Inc.
Inari Medical, Inc. is a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases. Our current product offering consists of two minimally invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The company purpose-built its products for the specific characteristics of the venous system and the treatment of the two distinct manifestations of venous thromboembolism, or VTE: deep vein thrombosis and pulmonary embolism. The ClotTriever system is 510(k)-cleared by FDA and CE marked for the non-surgical removal of clot from peripheral blood vessels, including for the use in the treatment of deep vein thrombosis. The FlowTriever system is 510(k)-cleared by FDA and CE marked for the non-surgical removal of clot from peripheral blood vessels, including for the use in the treatment of pulmonary embolism and clot in transit in the right atrium.

Investor Contact:
ICR Westwicke
Caroline Corner
Phone +1-415-202-5678
caroline.corner@westwicke.com

FAQ

What is the date of Inari Medical's first Analyst and Investor Day?

Inari Medical's first Analyst and Investor Day is scheduled for September 15, 2022.

Where will Inari Medical's Analyst and Investor Day take place?

The event will be held at Inari Medical's headquarters in Irvine, California.

What time does Inari Medical's Analyst and Investor Day start?

The webcast for Inari Medical's Analyst and Investor Day will commence at 9 a.m. Pacific Time.

How can I participate in Inari Medical's Analyst and Investor Day?

Interested participants can pre-register for the event via the link provided in the press release.

Will there be a replay of Inari Medical's Analyst and Investor Day presentation?

Yes, a live webcast replay will be accessible for 90 days on Inari Medical's Investor Relations website.

What products does Inari Medical focus on?

Inari Medical specializes in medical devices for treating venous diseases, particularly focusing on thrombectomy devices for deep vein thrombosis and pulmonary embolism.